Cholesterol-Lowering Drugs and Incident Open-Angle Glaucoma: A Population-Based Cohort Study by Marcus, Michael W. et al.
Cholesterol-Lowering Drugs and Incident Open-Angle
Glaucoma: A Population-Based Cohort Study
Michael W. Marcus
1, Rogier P. H. M. Mu ¨skens
1, Wishal D. Ramdas
2,3, Roger C. W. Wolfs
2,3, Paulus T. V. M.
De Jong
4,5, Johannes R. Vingerling
2,3, Albert Hofman
2, Bruno H. Stricker
2,6,7*, Nomdo M. Jansonius
1,2
1Department of Ophthalmology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 2Department of Epidemiology, Erasmus
Medical Center, Rotterdam, The Netherlands, 3Department of Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands, 4Department of
Ophthalmogenetics, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands, 5Department of Ophthalmology, Academic Medical Center, Amsterdam,
The Netherlands, 6Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, 7Department of Medical Informatics, Erasmus Medical Center,
Rotterdam, The Netherlands
Abstract
Background: Open-angle glaucoma (OAG) is a progressive neurodegenerative disease that may lead to blindness. An
elevated intraocular pressure (IOP) is its major risk factor. OAG treatment is currently exclusively directed towards the
lowering of the IOP. IOP lowering does not prevent disease progression in all patients and thus other treatment modalities
are needed. Earlier studies reported cholesterol-lowering drugs to have neuroprotective properties. The aim of this study
was to determine the associations between the use of cholesterol-lowering drugs and incident OAG.
Methodology/Principal Findings: Participants in a prospective population-based cohort study underwent ophthalmic
examinations, including IOP measurements and perimetry, at baseline and follow-up. The use of statins and non-statin
cholesterol-lowering drugs was monitored continuously during the study. Associations between the use of cholesterol-
lowering drugs and incident OAG were analyzed with Cox regression; associations between cholesterol-lowering drugs and
IOP at follow-up were analyzed with multiple linear regression. During a mean follow-up of 9.8 years, 108 of 3939 eligible
participants (2.7%) developed OAG. The hazard ratio for statin use was 0.54 (95% confidence interval 0.31–0.96; P=0.034)
and for non-statin cholesterol-lowering drugs 2.07 (0.81–5.33; P=0.13). The effect of statins was more pronounced with
prolonged use (hazard ratio 0.89 [0.41–1.94; P=0.77] for use two years or less; 0.46 [0.23–0.94; P=0.033] for use more than
two years; P-value for trend 0.10). The analyzes were adjusted for age and gender, baseline IOP and IOP-lowering treatment,
the family history of glaucoma, and myopia. There was no effect of statins on the IOP.
Conclusions/Significance: Long-term use of statins appears to be associated with a reduced risk of OAG. The observed
effect was independent of the IOP. These findings are in line with the idea that statins have neuroprotective properties and
may open a way to a new OAG treatment modality.
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Introduction
Open-angle glaucoma (OAG) is a progressive neurodegenera-
tive disease that leads to glaucomatous optic neuropathy and
eventually, through glaucomatous visual field loss, to loss of sight.
Together with age-related maculopathy it is the most common
cause of irreversible blindness. An elevated intraocular pressure
(IOP) is the major risk factor of OAG, and OAG treatment is
currently exclusively directed towards the lowering of the IOP.
However, OAG progression often continues despite an apparently
sufficient reduction of the IOP. For that reason, the search for
other OAG treatment modalities is a very active field of research.
Statins are selective inhibitors of 3-hydroxyl-3-methylglutaryl
coenzyme A reductase (HMG-CoA) [1]. Currently, they are the
most important lipid lowering medications for the treatment of
hypercholesterolemia [2–4]. Previous studies have reported
beneficial effects of statins on a variety of eye diseases, including
age-related maculopathy, cataract and diabetic retinopathy [5–
11]. Several observational studies addressed the effects of statins on
OAG. Some reported a protective effect [12–14] whereas others
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trials have reported neuroprotective properties of statins [17–22].
Since OAG is characterized by the loss of neuronal cells, the use of
statins, and possibly non-statin cholesterol-lowering drugs
(NSCLDs) as well, might modify the risk of OAG through
neuroprotection. With the current recommendations of lower
primary prevention thresholds [23,24], the use of statins and
NSCLDs has increased markedly over the years [25]. For these
reasons, it is expedient to clarify the associations between these
drugs and OAG.
The aim of the present study was to determine the associations
between the use of cholesterol-lowering drugs and incident OAG
in a large prospective population-based cohort study.
Methods
Ethics statement
All measurements were conducted after the Medical Ethics
Committee of the Erasmus University Rotterdam had approved
the study protocol and all participants had given written informed
consent in accordance with the declaration of Helsinki.
Study population
The present study was performed as part of the Rotterdam
Study, a prospective population-based cohort study investigating
age-related disorders. The study population consisted of 7983
individuals aged 55 years and older living in the Ommoord district
of Rotterdam, the Netherlands [26]. For this study, data from
3939 participants who did not have OAG (see below) at baseline
and who completed at least one follow-up examination were used.
The baseline examination took place from 1991 to 1993; follow-up
examinations were performed from 1997 to 1999 and from 2002
to 2006.
Ophthalmic assessment
Participants underwent similar eye examinations at baseline and
at the two follow-up rounds [27]. These examinations included
refraction, measurement of the best-corrected visual acuity,
Goldmann applanation tonometry (Haag-Streit AG, Bern, Swit-
zerland), fundoscopy, fundus photography of the posterior pole,
simultaneous stereoscopic fundus photography of the optic disc,
and visual field testing.
At each visit, three IOP measurements were taken on each eye
and the median value of these three measurements was recorded
[28]; the higher median of both eyes was used in the analysis. The
visual field of each eye was screened using a 52-point supra-
threshold test that covered the central visual field with a radius of
24u (Humphrey Field Analyzer [HFA]; Carl Zeiss, Oberkochen,
Germany) [27,29]. Visual field loss was defined as non-response to
a light stimulus of 6 dB above a threshold-related estimate of the
hill of vision in at least three contiguous test points, or four
including the blind spot. In participants with reproducible
abnormalities on supra-threshold testing, Goldmann perimetry
(Haag-Streit AG, Bern, Switzerland; baseline and first follow-up)
or full-threshold HFA 24-2 testing (second follow-up) was
performed on both eyes. Visual field loss was considered to be
glaucomatous visual field loss only if reproducible and after
excluding all other possible causes [29,30].
Incident open-angle glaucoma
We defined incident OAG as no glaucomatous visual field loss
in both eyes at baseline and glaucomatous visual field loss in at
least one eye at follow-up [30]. All identified cases were examined
by an experienced ophthalmologist (PTVMdJ and RCWW) who
performed gonioscopy and a dilated ophthalmic exam. Cases with
a history or signs of angle closure or secondary glaucoma were
excluded.
Medication data
Data on cholesterol-lowering drugs prescriptions for all
participants were obtained from seven fully automated pharmacies
using a centralized computer network in the study district, from
January 1, 1991, onward. This included the product name,
Anatomical Therapeutic Chemical (ATC) code, duration of use,
and the date of first prescription. Cholesterol-lowering drugs were
classified as statins (C10AA; simvastatin, pravastatin, fluvastatin,
atorvastatin, cerivastatin, rosuvastatin) or NSCLDs (C10AB,
C10AC, C10AD, C10A; fibrates, bile acid-binding resins or
nicotinic acid and derivatives). The use of cholesterol-lowering
drugs was recorded as the number of days with use during follow-
up. Usage before baseline was not taken into account.
Other covariates
Other covariates included age, gender, smoking, diabetes
mellitus, cardiovascular diseases, the use of antihypertensive drugs,
body mass index, total cholesterol, IOP, IOP-lowering treatment,
and family history of glaucoma. All these covariates were
measured at baseline. Smoking status was self reported and
categorized as ever or never smoker. Data on diabetes mellitus and
cardiovascular disorders such as angina pectoris, atrial fibrillation,
myocardial infarction, heart failure, hypertension, and stroke were
obtained from the participants through interviews, electrocardio-
gram readings, and non-fasting and fasting serum blood glucose
levels. Diabetes was defined as the use of antidiabetic medication
or by a non-fasting or post-load plasma glucose level above
200 mg/dl (11.1 mmol/l). Hypertension was defined as the use of
antihypertensive medication for the indication of hypertension or
as a systolic blood pressure of 140 mmHg or more, or a diastolic
pressure of 90 mmHg or more. Body mass and height were
measured at the research center. Total serum cholesterol was
measured in non-fasting blood. IOP-lowering treatment was
defined as the use of IOP-lowering medication or a history of
glaucoma surgery or laser trabeculoplasty. The family history of
glaucoma was determined by interviews and was considered
positive if the participant reported a history of glaucoma in
parents, siblings or offspring. Myopia was defined as a spherical
equivalent refractive error of 24 D and more myopia [30]. Eyes
with a cataract extraction before baseline were excluded from this
analysis. In cases with one eye with incident OAG, the refraction
of that eye was used. In participants without OAG or OAG in
both eyes, the refraction of a random eye was used.
Statistical analysis
Differences in baseline characteristics between participants with
and without incident OAG and differences in baseline character-
istics between cholesterol-lowering drug users and non-users were
evaluated using chi-square tests for categorical variables and t-tests
for normally distributed continuous variables. To determine the
associations between the use of cholesterol-lowering drugs and
incident OAG, the use of statins or NSCLDs was initially defined
as any use during follow-up and the associations were initially
analyzed with chi-square tests. Subsequently, a Cox proportional
hazards model was used to calculate hazard ratios (HR) and
corresponding 95% confidence intervals (CI) for the associations
Cholesterol-Lowering Drugs and Glaucoma
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29724between the use of statins or NSCLDs and incident OAG. Follow-
up duration was used as the time axis in the model. For
participants without incident OAG, the follow-up duration was
counted from the baseline visit to the last visit with reliable
perimetry. For incident OAG cases, the follow-up ended at the
first visit in which glaucomatous visual field loss was detected. The
cholesterol-lowering drugs, age and gender, and other covariates
with P,0.20 in the univariate comparisons were included in the
multivariate analysis. Subsequently, the cholesterol-lowering
drugs, age and gender, and other covariates with P,0.05 in the
initial multivariate model were included in the final model. The
use of cholesterol-lowering drugs was entered in the model as any
use during follow-up. To allow for the evaluation of a possible
dose-response relationship, we also performed analysis after
making three nominal categories based on the duration of
medication use, being no use, cumulative use during two years
or less, and cumulative use during more than two years (see
Discussion section). The dose-response relationship was evaluated
with a trend test. To explore the influence of cholesterol-lowering
drugs on the IOP, we conducted a multiple linear regression
analysis with IOP at follow-up as the dependent variable. This
analysis was adjusted for IOP-lowering treatment at follow-up and
for the same covariates as the final Cox model except for baseline
IOP and IOP-lowering treatment at baseline. All analyzes were
performed using SAS 9.2 (SAS Institute Inc., Cary, NC). A P-value
of 0.05 or less was considered statistically significant.
Results
During a mean follow-up of 9.8 years, 108 of 3939 eligible
participants (2.7%) developed OAG. Table 1A depicts the baseline
characteristics of the study population for participants with and
without incident OAG. Participants with incident OAG were
older, more often male, more often had a positive family history of
glaucoma, and more often had myopia. They also had a higher
IOP and more frequently received IOP-lowering treatment. There
was no difference between the groups regarding total serum
cholesterol levels. Table 1B shows the baseline characteristics for
cholesterol-lowering drug users and non-users. Participants using
cholesterol-lowering drugs were younger, smoked less frequently
and more often had diabetes mellitus, a myocardial infarction or
hypertension. They also used more often antihypertensive drugs
and had a higher total serum cholesterol level and a slightly higher
IOP.
Table 2 presents the results of the univariable analyses for the
use of statins and NSCLDs at any time during follow-up. These
univariable comparisons revealed no significant differences
between participants with and without incident OAG. Amongst
the 811 participants using statins at any time during follow-up, the
median duration of use was 1424 days, with a range from 8 to
4114 days; amongst the 113 participants using NSCLDs, the
median duration of use was 298 days, with a range from 7 to 3544
days.
Table 3 presents the final multivariate model, adjusting for age
and gender, baseline IOP and IOP-lowering treatment, the family
history of glaucoma, and myopia. Participants using statins had a
significant risk reduction (HR 0.54; 95% CI 0.31 to 0.96;
P=0.034). The use of NSCLDs was not significantly associated
with incident OAG (HR 2.07; 95% CI 0.81 to 5.33; P=0.13).
There was a trend towards a reduced risk of incident OAG with
prolonged statin use. The HR was 0.89 (95% CI 0.41 to 1.94,
P=0.77) for use during two years or less and 0.46 (95% CI 0.23 to
0.94, P=0.033) for use during more than two years. The overall P-
value for trend was 0.10.
The protective effect of statins could be either caused by an
IOP-lowering effect of statins or by a direct protective effect of
statins on the neural tissue. To differentiate between these two
possibilities, we conducted a multiple linear regression analysis
with IOP at follow-up as the dependent variable. Table 4 shows
the results. As can be seen in this table, there was no significant
IOP-lowering effect of statins.
Discussion
In this large prospective population-based study, the use of
statins was associated with a reduced risk of OAG. This effect was
independent of the IOP. The risk reduction tended to increase
with the duration of cumulative use, which supports the observed
association, but this trend did not reach statistical significance. The
use of NSCLDs was not associated with the development of OAG.
The association between the use of statins and OAG we found is
consistent with the results of McGwin et al. (odds ratio 0.60; 95%
CI 0.39 to 0.92) [12]. They performed a nested case-control study
in a clinical administrative database. In contrast, Owen et al.
found no evidence for a protective effect of statins (odds ratio 0.97;
95% CI 0.88 to 1.06) [15]. They employed a case-control study
design in a primary care database. Similarly, Iskedjidan et al. did
not find a significant association between the use of statins and
OAG [16]. They performed a retrospective population-based
evaluation in an administrative prescription claims database. The
designs of the latter two studies might have complicated the
classification of OAG, and the resulting misclassification might
have biased the effect estimate. The trend of the effect seen in our
study is consistent with previously published studies. McGwin et al.
reported a significant reduction in the risk of OAG in patients
using statins for more than 23 months [12]. De Castro et al.
reported that the use of statins was associated with a slower
progression of glaucomatous optic nerve atrophy [14]. In their
clinical retrospective cohort study, patients using statins for two
years showed less optic nerve head changes than patients not using
statins. Nagaoka, et al studied the effect of statins on the retinal
circulation and the IOP [31]. They found an IOP decrease after
the administration of statins. At first sight, this seems to
corroborate with our findings. However, our data suggested the
protective effect of statins to be IOP independent. A possible
explanation for this discrepancy might be that they studied the
effects of statins up to one week after the initial administration
whereas we found the most pronounced effect in those OAG cases
that used statins for more than two years. Leung et al. reported
that the use of simvastatin was associated with visual field
stabilization in patients with normal tension glaucoma (relative
risk 0.36; 95% CI 0.14 to 0.91; P=0.030) [13]. In their
prospective cohort study, 256 patients with normal tension
glaucoma of whom thirty-one were taking simvastatin and 225
were not taking simvastatin were followed-up for 36 months.
The use of NSCLDs was not associated with incident OAG in
our study. This result contradicts the result of the study by
McGwin et al. who found a protective effect among those who
used NSCLDs (odds ratio 0.59; 95% CI 0.37 to 0.97) [12]. This
discrepancy might be attributed to the low number of users of
NSCLDS in our study, as depicted by the wide CIs.
Strengths of our study include its prospective design, the large
number of participants, the long follow-up period and the
population-based setting, which minimizes selection bias. An
inextricable limitation of the population-based design is the limited
Cholesterol-Lowering Drugs and Glaucoma
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open-angle glaucoma.
Incident open-angle glaucoma (N=108) No incident open-angle glaucoma (N=3831) P-value
Statins (n[%]) 16(14.8) 795(20.8) 0.13
NSCLDs (n[%]) 5(4.6) 108(2.8) 0.27
NSCLDs=non-statin cholesterol-lowering drugs.
doi:10.1371/journal.pone.0029724.t002
Table 1. Baseline characteristics of participants with and without incident open-angle glaucoma (A) and of cholesterol-lowering
drug users (either statins or NSCLDs, or both) and non-users (B), with univariable comparisons (mean values with standard
deviation between brackets unless stated otherwise).
A
Incident open-angle glaucoma
(N=108)
No incident open-angle
glaucoma
(N=3831) P-value
Age (year) 68.4(7.1) 65.7(6.8) ,0.001
Gender (%female) 49.1 58.7 0.046
Smoking (%) 33.3 33.4 0.98
Diabetes mellitus (%) 8.4 6.9 0.54
Angina pectoris (%) 1.9 3.1 0.46
Atrial fibrillation (%) 2.8 2.1 0.63
Myocardial infarction (%) 13.2 9.7 0.23
Heart failure (%) 0.9 1.2 0.81
Hypertension (%) 52.9 47.1 0.49
Blood pressure lowering drugs (%) 28.0 26.0 0.63
Stroke (%) 2.8 1.2 0.16
Body mass index (kg/m
2) 25.8(2.9) 26.3(3.5) 0.12
Total cholesterol (mmol/l) 6.5(1.1) 6.7(1.2) 0.17
IOP (mmHg) 17.3(4.7) 15.0(3.1) ,0.001
IOP-lowering treatment (%) 15.7 2.3 ,0.001
Family history of glaucoma (%) 16.7 8.1 0.002
Myopia 9.5 4.9 0.033
B
Cholesterol-lowering drug users
(N=848)
Non-users
(N=3091)
Age 64.3(5.5) 66.1(7.1) ,0.001
Gender (%female) 56.6 58.9 0.23
Smoking (%) 27.5 35.0 ,0.001
Diabetes mellitus (%) 10.2 6.1 ,0.001
Angina pectoris (%) 3.8 2.8 0.15
Atrial fibrillation (%) 2.4 2.1 0.57
Myocardial infarction (%) 15.3 8.2 ,0.001
Heart failure (%) 1.2 1.2 0.97
Hypertension (%) 58.7 47.1 ,0.001
Blood pressure lowering drugs (%) 38.3 22.6 ,0.001
Stroke (%) 1.4 1.2 0.65
Body mass index (kg/m
2) 26.5(3.5) 26.2(3.5) 0.055
Total cholesterol (mmol/l) 7.4(1.3) 6.5(1.1) ,0.001
IOP (mmHg) 15.3(3.2) 15.0(3.2) 0.044
IOP-lowering treatment (%) 2.0 2.9 0.18
Family history of glaucoma (%) 9.7 8.0 0.13
Myopia 6.3 4.7 0.063
NSCLDs=non-statin cholesterol-lowering drugs; IOP=intraocular pressure.
doi:10.1371/journal.pone.0029724.t001
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the limited number of participants using NSCLDs. Information
bias was prevented by prospectively collected and completely
automated pharmacy records of all prescriptions. Although this
approach guarantees accurate prescription data, it cannot be
guaranteed that all participants actually took their medication.
Such exposure misclassification is usually similar in cases and
controls and leads to conservative risk estimates. Hence, it may
have contributed to the lack of effect of NSCLDs, but not to the
protective effect of statins.
Several other factors have been reported to be a risk factor for the
incidence of OAG, including myopia [32], pseudoexfoliation [33],
central corneal thickness [34], and age [30]. Of these factors, only
pseudoexfoliation and age may be associated with statin use and
may thus be confounding factors in our analysis [35–37].
Pseudoexfoliation is relatively rare in the Netherlands and in our
study population (which might or might not be due to underre-
porting) – hampering a meaningful adjustment for pseudoexfolia-
tion in our analysis. However, the absence of adjustment should
have resulted in an increased risk whereas we found a protective
effect. Age is associated with statin use but we adjusted our models
for that. Age as a linear covariable – as we did – might result in
under-adjustment, but in that case an increased risk should have
been the result, not a protective effect. We included only
participants aged 55 years and older. This is not a limitation for
this specific study question, as both statin use at younger age is
relatively rare and the prevalence of OAG below 55 years of age is
very low (0.1–0.2%; to be compared to 1–2% above 55 years of age
[27]. Finally, myopia appeared to occur – presumably by chance –
slightly more frequent amongst cholesterol-lowering drug users
compared to non-users (P=0.063; Table 1B) and was included in
the final model.
A possible limitation of this study is potential misclassification of
exposure. However, such misclassification will be random because
the outcome is – inextricably - gathered irrespective of exposure
status. To appreciate this approach, it is important to realize that
glaucoma development often takes more than a decade and
cannot be detected in the earliest stages. Some factors slow down
or accelerate the disease development, and thus make it less likely
or more likely that the disease can be detected at a certain point in
time (being our follow-up examination). Cumulative exposure
stratified into biologically plausible nominal categories as we used
in our analyses is the best proxy for studying the overall influence
of the use of medication on the rate of glaucoma development
during follow-up. Details of this technique were published earlier
[38]. Because the exposure misclassification is random, it will tend
to bias the results towards the null hypothesis. This might mean
that the significant protection we found is an underestimation of
the true effect.
Our finding of a protective effect of statins may offer potential
therapeutic possibilities for OAG or its prevention. We showed the
effect to be independent of the IOP. Hence, the protective effect of
statins could be caused by lowering serum cholesterol or by (other)
neuroprotective properties of statins on neuronal cells, as
mentioned in the Introduction section [17–22]. Our incident
OAG cases did not have an elevated serum cholesterol level at
baseline (Table 1), but that observation does not exclude a
beneficial effect of a further lowering of this level - cardiovascular
trials have shown beneficial effects of further lowering cholesterol
levels even if initially already within normal limits [39,40]. Studies
with serum cholesterol level monitoring during follow-up should
enable the uncovering of more details of the mechanism
underlying the protective effect of statins. Given the current level
of evidence and the fact that statins are widely available and
thoroughly investigated drugs, a neuroprotective OAG treatment
could become reality and a randomised clinical trial seems to be a
viable next step.
In conclusion, we confirmed that statins appear to have a
protective effect on OAG. Due to our study design, we were able
to add that this protective effect is IOP independent. Hence,
statins should be further explored as a new class of medications for
the treatment of OAG, especially for those patients in whom
disease progression continues despite an apparently sufficient IOP
reduction.
Table 4. Multiple linear regression analysis with intraocular pressure at follow-up as the dependent variable.
beta 95% confidence interval P-value
Statins 20.006 20.262–0.249 0.96
Age (year) 20.011 20.026–0.005 0.18
Gender (female) 20.269 20.479–20.060 0.012
IOP-lowering treatment at follow-up 1.761 1.340–2.181 ,0.001
Family history of glaucoma 0.378 0.001–0.755 0.050
Myopia 0.597 0.124–1.069 0.013
IOP=intraocular pressure.
doi:10.1371/journal.pone.0029724.t004
Table 3. Final multivariate model of the risk of developing
open-angle glaucoma for cholesterol-lowering medication.
Hazard ratio
95% confidence
interval P-value
Statins 0.54 0.31–0.96 0.034
NSCLDs 2.07 0.81–5.33 0.13
Age (per year) 1.07 1.04–1.10 ,0.001
Gender (female) 0.56 0.38–0.83 0.004
IOP (per mmHg) 1.12 1.08–1.18 ,0.001
IOP treatment 3.39 1.82–6.32 ,0.001
Family history of glaucoma 1.85 1.08–3.15 0.024
Myopia 2.30 1.19–4.43 0.013
NSCLDs=non-statin cholesterol-lowering drugs; IOP=intraocular pressure.
doi:10.1371/journal.pone.0029724.t003
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